have a question, issue or just some feedback for us? we're here for you.

what can we help you with?

let us know how we can help

DISCLAIMER

The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.

compose your message

to*

from*

subject

message

message sent

email sent successfully

suggest a poll

you must have an account to suggest polls.

join now

You are receiving this because you have an account on www.oneGRAVESvoice.com
To unsubscribe from these emails, click here

Trusted Resources: News & Meetings

Latest announcements and gatherings

Clinical Trials And Research
Business
People
Spotlight
Happenings
Fundraising Events

Back to News & Meetings / Spotlight

New Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)

Horizon Therapeutics plc announced positive topline data from two clinical trials that add to the growing body of evidence supporting the efficacy and safety of TEPEZZA® (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED). TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of TED – a serious, progressive and vision-threatening rare autoimmune disease.

The OPTIC Phase 3 confirmatory clinical trial and the OPTIC-X open-label extension clinical trial are part of Horizon’s development program to evaluate the safety and efficacy of TEPEZZA in people living with TED. The OPTIC Phase 3 confirmatory clinical trial included a 24-week treatment period and a 48-week off-treatment follow-up period. The OPTIC 24-week treatment period evaluated patients who received TEPEZZA or placebo once every three weeks for a total of eight infusions.

Source: https://www.businesswire.com/news/home/20200731005101/en/

Discuss in Social Wall

Twitter

Share to rareTeam

myBinder

send a message

send to:
subject:
message:

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Trusted Resources Home

Evidence & Education

People & Places

News & Meetings

Videos & Visuals

Partner Pages

New Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)

Related Content

Powered by

Trusted Resources Home

Evidence & Education

People & Places

Community Center

News & Meetings

Videos & Visuals

Partner Pages

Trusted Resources: News & Meetings

Latest announcements and gatherings

New Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)

Related Content

Powered by